PepGen Inc. (PEPG)
NASDAQ:PEPG
Want to see PEPG full AI Analyst Report?
PEPG Stock Chart & Stats
$1.70
-$0.11(-3.01%)
At close: 4:00 PM EST
$1.70
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$1.01 - $7.80
Previous CloseN/A
Volume7.67K
Average Volume (3M)6.68M
Market Cap
$123.81M
Enterprise Value$92.00M
Total Cash (Recent Filing)$132.30M
Total Debt (Recent Filing)$16.56M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 06, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding69,169,210
10 Day Avg. Volume930,736
30 Day Avg. Volume6,679,177
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.86
Price to Sales (P/S)0.00
P/FCF Ratio-3.36
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-53.61
Enterprise Value/Ebitda-1.21
Forecast
1Y Price Target
$10.17Price Target Upside498.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformPepGen's Enhanced Delivery Oligonucleotide (EDO) platform demonstrably increases nuclear oligonucleotide delivery and splicing correction, providing a durable technical moat that can improve therapeutic efficacy across multiple RNA-targeted programs and support licensing or partnership value over time.
Clinical Program MomentumOngoing FREEDOM and FREEDOM2 studies reporting tolerability and emerging biomarker signals indicate program de-risking. Continued global enrollment and upcoming higher-dose cohort readouts in 2026–27 could materially advance clinical validation and catalyze regulatory or partner interest long-term.
Conservative LeverageLow historical leverage (debt/equity ~0.12) and a meaningful equity cushion reduce near-term refinancing risk and provide financial flexibility to advance trials. This conservative capital structure is a durable balance-sheet strength for a pre-commercial biotech facing future financing cycles.
Bears Say
High Cash BurnSustained negative operating and free cash flow near -$77M TTM implies continual funding needs. Over the coming months, persistent burn will pressure liquidity and likely require equity or partnership funding, diluting shareholders or altering strategic priorities if cost reductions aren't achieved.
Pre-commercial No RevenueThe company remains pre-commercial with no product revenues and large recurring operating losses. Without commercialization or material partnership income, the business depends on external capital to sustain development, keeping profitability and cash-flow improvement distant and uncertain.
Regulatory/Trial RiskA partial FDA clinical hold on the U.S. arm increases timeline and execution risk for a lead program. Regulatory holds can delay enrollment, raise monitoring costs, and complicate global development plans, making near-term clinical readouts and approval pathways less certain.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $1.01 and its highest was $7.80 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $123.81M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 47 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on May 12, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.293 by $0.033.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.28.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 69,169,210 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.293. Following the earnings report the stock price went up 5.952%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PepGen Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.17 (498.04% Upside)
$10.17 (498.04% Upside)
Hedge Fund Trend
Decreased
By 865.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
-59.89%
Trailing 12-Months
Asset Growth
22.69%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc. is a clinical-stage biopharmaceutical company specializing in the development of oligonucleotide therapeutics designed to treat severe neuromuscular and neurological disorders. Its most advanced candidate, PGN-EDO51 – an EDO peptide – is currently undergoing Phase 1 clinical trials for individuals suffering from Duchenne muscular dystrophy (DMD). The company's pipeline also includes PGN-EDODM1, an EDO peptide-conjugated PMO aimed at myotonic dystrophy type 1, alongside other EDO therapeutic candidates for DMD, specifically PGN-EDO53, PGN-EDO45, and PGN-EDO44. Established in 2018, PepGen Inc. operates from its headquarters in Cambridge, Massachusetts.
PEPG Stock 12 Month Forecast
Average Price Target
$10.17
▲(498.04% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
―
Lyell Immunopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
37.05% Insiders
3.69% Mutual Funds
4.24% Other Institutional Investors
51.24% Public Companies and
Individual Investors